Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

BACKGROUND: Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionall...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Larsen, Julie Rask, Vedtofte, Louise, Holst, Jens Juul, Oturai, Peter, Kjær, Andreas, Corell, Christoph U, Vilsbøll, Tina, Fink-Jensen, Anders
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2014
Assuntos:
Diabetes and Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3975765/
https://ncbi.nlm.nih.gov/pubmed/24667381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2013-004227
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados